Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

被引：77

作者：

Stuver, Robert ^{[1
]}

Shah, Gunjan L. ^{[2
]}

Korde, Neha S. ^{[3
]}

Roeker, Lindsey E. ^{[4
]}

Mato, Anthony R. ^{[4
]}

Batlevi, Connie L. ^{[1
]}

Chung, David J. ^{[2
]}

Doddi, Sital ^{[5
]}

Falchi, Lorenzo ^{[1
]}

Gyurkocza, Boglarka ^{[2
]}

Hamilton, Audrey ^{[1
]}

Lin, Ya-Hui ^{[5
]}

Jakubowski, Ann A. ^{[2
]}

Joffe, Erel ^{[1
]}

Landau, Heather L. ^{[2
]}

Lin, Richard J. ^{[2
]}

Mailankody, Sham ^{[3
]}

Palomba, M. Lia ^{[1
]}

Park, Jae H. ^{[4
]}

Perales, Miguel-Angel ^{[2
]}

Ponce, Doris M. ^{[2
]}

V. Ramanathan, Lakshmi ^{[5
]}

Salles, Gilles A. ^{[1
]}

Scordo, Michael ^{[2
]}

Seo, Susan K. ^{[6
]}

Shah, Urvi A. ^{[3
]}

Stein, Eytan M. ^{[4
]}

Straus, David ^{[1
]}

Usmani, Saad Z. ^{[3
]}

Young, James W. ^{[2
]}

Zelenetz, Andrew D. ^{[1
]}

Noy, Ariela ^{[1
]}

Vardhana, Santosha A. ^{[1
,7
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, Div Subspecialty Med, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER CELL | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1016/j.ccell.2022.05.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：590 / 591

页数：2

共 50 条

[41] SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients
Reis, C.
Madigan, T.
Ristagno, E.
AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S390 - S390
[42] SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients
Reis, Christopher A.
Ristagno, Elizabeth H.
Madigan, Theresa
CLINICAL TRANSPLANTATION, 2024, 38 (07)
[43] Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era
Vergori, Alessandra
Lepri, Alessandro Cozzi
Chiuchiarelli, Marta
Mazzotta, Valentina
Metafuni, Elisabetta
Matusali, Giulia
Siciliano, Valentina
Paulicelli, Jessica
Alma, Eleonora
Siniscalchi, Agostina
Sica, Simona
Abruzzese, Elisabetta
Fantoni, Massimo
Antinori, Andrea
Cingolani, Antonella
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 144
[44] Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients
Jordan, Stanley C.
Joung, Sandy Y.
Wang, Minhao
Tran, Teresa Anh
Bravo, Michelle
Masoom, Hibah
Chang, Christine
Mendez, Marilyn
Patel, Jignesh
Sun, Nancy
Kittleson, Michelle
Frias, Edwin
Prostko, John C.
Ebinger, Joseph E.
Cheng, Susan
Sobhani, Kimia
TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (01)
[45] Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies
Zitvogel, Laurence
Derosa, Lisa
Kroemer, Guido
BLOOD CANCER DISCOVERY, 2023, 4 (03): : 172 - 175
[46] Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients
Marti-Pastor, Marc
Bou-Monterde, Ricardo
Ciancotti-Oliver, Lucia
Alcover-Pons, Marta
Cantero, Aurora Amoros
Sanchez-Lopezosa, Raquel
Montanana-Rosell, Neus
MEDICINA CLINICA, 2024, 163 (06): : 275 - 280
[47] Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study
Lendacki, Frances R.
Li, Linda
Forrest, Graeme N.
Jordan, Leirah
Zelinski, Christy
Black, Stephanie R.
Ison, Michael G.
Seo, Jennifer Y.
TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (01)
[48] Retrospective Analysis of a Real-Life Use of Tixagevimab-Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19
Capoluongo, Nicolina
Mascolo, Annamaria
Bernardi, Francesca Futura
Sarno, Marina
Mattera, Valentina
di Flumeri, Giusy
Pustorino, Bruno
Spaterella, Micaela
Trama, Ugo
Capuano, Annalisa
Perrella, Alessandro
PHARMACEUTICALS, 2023, 16 (10)
[49] The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry
Luttwak, Efrat
Noy, Ariela
Seshan, Venkatraman
Saltzman, Larry A.
Greenberger, Lee M.
LEUKEMIA & LYMPHOMA, 2023, 64 (10) : 1727 - 1729
[50] Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies
Aiello, Tommaso Francesco
Peyrony, Olivier
Chumbita, Mariana
Monzo, Patricia
Lopera, Carlos
Puerta-Alcalde, Pedro
Magnano, Laura
Fernandez-Aviles, Francesc
Cuesta, Genoveva
Tuset, Montse
Mensa, Josep
Esteve, Jordi
Marcos, Maria Angeles
Soriano, Alex
Garcia-Vidal, Carolina
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (03)

← 1 2 3 4 5 →